Sidhu M S, Kent D R
Obstet Gynecol. 1984 Jul;64(1):128-30.
The purpose of the present clinical investigation was to determine the effect of preoperative treatment with a long-acting prostaglandin suppository containing 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 on uterine blood loss in patients undergoing preoperative cervical dilatation before transcervical abortion. Ninety-five young women in the ninth to 14th week of gestation were randomly assigned to one of two groups. Patients in group 1 were treated with a long-acting prostaglandin suppository and group 2 patients acted as control subjects. At the end of three hours, patients in both groups underwent abortion with careful intraoperative measurement of blood loss in both groups. The blood loss in the prostaglandin-treated group was significantly lower than that in the control group (69.0 +/- 14.1 mL versus 151.1 +/- 26.6 mL). The difference in intraoperative blood loss was observed at all gestations between nine and 14 weeks. There was significantly greater dilation of the cervix after prostaglandin treatment (mean difference, 4.58 mm; P less than .005).
本临床研究的目的是确定术前使用含9-脱氧-16,16-二甲基-9-亚甲基前列腺素E2的长效前列腺素栓剂对经宫颈流产术前宫颈扩张患者子宫失血量的影响。95名妊娠9至14周的年轻女性被随机分为两组。第1组患者接受长效前列腺素栓剂治疗，第2组患者作为对照。三小时结束时，两组患者均接受流产手术，并仔细测量两组术中失血量。前列腺素治疗组的失血量显著低于对照组（69.0±14.1毫升对151.1±26.6毫升）。在9至14周的所有孕周均观察到术中失血量的差异。前列腺素治疗后宫颈扩张明显更大（平均差异4.58毫米；P<0.005）。
